CASE REPORT

Effect of chemotherapy on autoimmune hepatitis in thymoma: a case report and literature review

Nesrine Mejri¹, Imen Chabchoub¹, Ines Gargouri¹, Imtinen Belaid¹, Faten Ezairi¹, Sihem Hmissa², Slim Ben Ahmed¹

¹Medical Oncology Department, Farhat Hached Hospital, Sousse 4011, Tunisia; ²Pathology Department, Farhat Hached Hospital, Sousse 4011, Tunisia

ABSTRACT

Autoimmune hepatitis (AIH) has rarely been described as an autoimmune paraneoplastic syndrome of thymoma. This case is the seventh case of AIH revealed by cholestasis few years after the diagnosis of thymoma and the first case treated with chemotherapy alone. We report in this paper a new approach to this rare severe condition. A 29 year-old man presented with chest pain and dyspnea with a history of thymoma surgically removed 4 years ago. CT scan showed the recurrence of an anterior mediastinal mass. Biology showed elevated liver enzymes and profound cholestasis. No sign of viral or toxic hepatitis or bile duct abnormalities were observed. Autoimmune antibodies, except for the anti-nuclear antibody, were negative. Liver biopsy showed active chronic AIH. The patient was diagnosed with recurrent thymoma with AIH and underwent 6 cycles of chemotherapy. A complete response on thymoma and cholestasis was obtained after 10 months of follow-up. Steroids and immunosuppressors are the standard treatment for AIH. The effect of chemotherapy as a specific treatment of this paraneoplastic syndrome needs to be considered.

KEYWORDS Hepatitis; autoimmune; thymoma; chemotherapy

Introduction

Thymoma is the most frequent tumor of the thymus. The 2004 WHO classification considers three morphological types of thymoma according to genetic alterations (microsatellite instability, 6q25, 5q21-22 mutations): A, B (B1, B2, and B3), and AB. The B3 subtype is the most aggressive one with 50% overall survival within 5 years¹. Median age at diagnosis is 50 years. Thymoma is a slow-growing tumor that can relapse after 10 years, implying lifelong follow-up. The rate of associated malignancy (e.g., lymphoma and lung sarcoma) is higher than that in the general population². Many autoimmune paraneoplastic syndromes are associated with thymoma. The most popular such syndrome is myasthenia gravis, which occurs in 35% to 45% of cases. Other autoimmune diseases have been

Correspondence to: Nesrine Mejri

Available at www.cancerbiomed.org

Copyright © 2013 by Cancer Biology & Medicine

reported, such as systemic lupus erythematosus, Hashimoto's thyroiditis, erythroblastopenia, type I diabetes mellitus, and in some cases, 2 or even 3 autoimmune diseases at the same time. Autoimmune hepatitis (AIH) associated with thymoma has rarely been reported, with fewer than 10 cases published in literature. AIH is a severe disease because it inhibits certain specific treatments of the primary tumor and destroys hepatic tissue and causes hepato-cellular failure.

We report a new case of AIH associated with thymoma. The new finding about this case is that chemotherapy reduces biological signs of hepatitis without need for steroids or immunosuppressors. Through this case report and a review of literature, we highlight the clinical and therapeutic aspects of this rare entity.

Case report

A 29 year-old male with dyspnea and chest pain was referred to our center. Medical history showed diabetes mellitus and B1 subtype thymoma (stage II) surgically removed 4 years ago (**Figure 1**). The patient did not receive adjuvant therapy at that time and was not followed up since.

E-mail: nesrinemejriturki@yahoo.fr

Received September 8, 2013; accepted September 28, 2013.

Physical examination showed no signs of heart failure or myasthenia gravis. ECG was normal. Chest X-ray revealed an enlargement of the upper mediastinum with small pleural effusion. CT scan showed a tissular mass of the anterior mediastinum with dimensions of 3 cm \times 5 cm \times 6 cm. This mass reached the mediastinum medium and came into contact with the pericardium. Small pleural and pericardial effusion was observed. Cytology examination of pleural liquid was negative. Core biopsy was technically difficult and life-threatening. The patient exhibited local recurrence of a thymic tumor. Chemotherapy was decided, and the patient was admitted to our center in March 2012.

Blood cell count, renal function, and calcemia were normal. We observed a biological inflammatory syndrome with accelerated sedimentation speed (90 in the first hour) and polyclonal hyper gamma-globulinemia (46 g/L), predominantly of type IgG. Profound cholestasis without pruritis or jaundice was observed: total bilirubin at 72 mg/dL ($5\times$ normal), gamma glutamyl transferase at 1,680 UI/L ($30\times$ normal), and alkaline phosphatase at 780 UI/L ($6\times$ normal). The level of aspartate aminotransferase (ASAT) was 56 UI/L ($1.5\times$ normal), and that of alanine aminotransferase (ALAT) was 63 UI/L ($1.5\times$ normal). Blood sugar levels were disturbed. No history of drug abuse, including herb consumption, was reported. Abdominal ultrasonography showed no liver or bile duct abnormalities. Viral markers of hepatitis B and C were negative. Anti-nuclear antibody content was high (1/800, type ant-DNA), and anti-



Figure 1 Type B thymoma, cytokeratine positive staining (IHC×40).

Table 1 Evolution of liver enzymes	;
---	---

mitochondrial antibodies, anti-liver/kidney microsomes (LKM1), and anti-smooth muscles were negative. A liver biopsy showed signs of active periportal necrosis and fibrosis with an infiltration of inflammatory cells, mainly lymphocytes and plasmocytes (**Figure 2**). According to the scoring system of the International AIH Group, the pre-treatment score was 13, which corresponds to the probable diagnosis of AIH.

The patient was subjected to 3 cycles of chemotherapy based on cyclophosphamide, cisplatine, doxorubicine, and vincristine (CACV, every three weeks), with 50% reduction of vincristine doses because of hepatic cholestasis. Steroids were not indicated because the diabetes of the patient was difficult to stabilize and cytolysis was low and thus could not indicate immediate treatment. No grade III/IV toxicity was observed. Evaluation after 3 cycles showed clinical relief, radiological complete response on the thymic tumor, partial regression of pleural effusion, and 50% reduction of biological cholestasis (Table 1). The post-treatment score was 17, which corresponds to a definitive diagnosis of AIH. Diabetes was stabilized with insulin doses. The patient received 3 more cycles of the same chemotherapy. CT scan evaluation showed partial regression of the pleural effusion and normal liver lab values. The patient was considered to be in complete remission. He was recommended for mediastinal radiotherapy. At the time of this writing, the patient is asymptomatic with normal cholestasis markers and CT scan after 14 months of follow-up.



Figure 2 Lymphocyte infiltration and paracellular necrosis (H&E×40).

Liver enzymes	Before chemotherapy	After 3 cycles of chemotherapy	After 6 cycles of chemotherapy
Gamma globulin (g/L)	46	35	24
Total bilirubin (mg/dL)	72	40	11
Gamma glutamyl transferase (UI/L)	1,680	1,050	230
Alkaline phosphatase(UI/L)	780	580	210
Aspartate aminotransferase (UI/L)	56	20	18
Alanine aminotransferase (UI/L)	63	22	20

Reference Age Gender Instantion Collocy (un) Evolution and solution Evolution and solution Evolution and solution Evolution and solution vis p presentation Normetrion Aux7135 Normetrion Evolution and solution Evolution and solution Ket of relation Aux7136 Normetrion Aux7136 Aux7137 Evolution and atter 2 months Hametrial 1 Aux7137 Aux7137 Aux7137 Aux7137 Aux7137 Hametrial 3 M Figue Aux7137 Aux7137 Aux7137 Auxetrial 3 M Figue Aux7130 No bile duct Chronic active hepatitis Myasthenia gravis Figue 100011 Advance Aux7130 No bile duct Chronic active hepatitis Myasthenia gravis Padnisolone AfX1/AT no Advance Aux01 No bile duct Chronic active hepatitis Myasthenia gravis Padnisolone Afx1/AT no Advance Aux01 Aux01 Normetrial Myasthenia gravis Padnisolone	Table 2 Clinic	al and t	therapeuti	ic aspects of c	ases reported in the li	terature				
yrs presentation Symptoms Symptoms Collowend Activation Collowend Activation Collowend Activation Collowend Activation Collowend Activation Collowend Activation	Reference	Age,	Gender	Clinical	Biology (UI/L)	Radiology	Pathology	Other paraneoplastic	Treatment	Evolution and
Ko et at. ¹ Zi F Incidental ASAT:1158 Not mentioned Activic chronic hepatitis Myasthenia gravis Perdinsolone ASAT/ALT nor PAL:106 ALAT:371 ALAT:371 Not ALAT:371 Polymyosite Asativippinine after 2 months PAL:106 ALAT:371 ALAT:371 Not ANA-		yrs		presentation				symptoms		follow up
ALAT: 943ALAT: 943ALAT: 943PolymyostieAziathiopirineafter 2 months $AN+$ $AN AN ASN AN AN AN AN AN AN AN AN ASN AN AN-$ <t< td=""><td>Ko <i>et al.</i>³</td><td>25</td><td>ш</td><td>Incidental</td><td>ASAT: 1158</td><td>Not mentioned</td><td>Active chronic hepatitis</td><td>Myasthenia gravis</td><td>Prednisolone</td><td>ASAT/ALAT normal</td></t<>	Ko <i>et al.</i> ³	25	ш	Incidental	ASAT: 1158	Not mentioned	Active chronic hepatitis	Myasthenia gravis	Prednisolone	ASAT/ALAT normal
Han et at^4 30MFatigueFAU:106Han et at^4 30MFatigueASAT:400No bile ductChronic active hepatitisMyastheniaPrednisoloneASAT/ALT norHan et at^4 30MFatigueASAT:300No bile ductChronic active hepatitisMyastheniaPrednisoloneASAT/ALT norAswaa et at^5 71JaundiceASAT:320No bile ductNo contractive hepatitisMyasthenia gravisPrednisoloneASAT/ALT norAswaa et at^5 71JaundiceASAT:320No bile ductNo contractive hepatitisMyasthenia gravisPlasmaphereseHepatitisAswaa et at^5 71JaundiceASAT:320No panenchymalChronic non suprurativeNo contractive hepatitisNo con					ALAT: 943			Polymyosite	Aziathiopirine	after 2 months
AN++ AN++ SM- SM- KM1- KM1- Han et al. ⁴ 30 M Faigue SA71.400 No bile duct Chronic active hepatitis Myasthenia AFA1/AUT/nor Aba+ KM1- ASA7.300 No bile duct Necropsied specimer: Diabetis Mellitis AFA1/Inor Ascris ALAT.280 dilatation auto immune hepatitis Myasthenia gravis Prednisolone AFA1/AUT/nor Ascris ALAT.280 dilatation auto immune hepatitis Myasthenia gravis Prednisolone AFA1/AUT/nor Ascris ALAT.280 dilatation auto immune hepatitis Myasthenia gravis Prednisolone AFA1/AUT/nor Ascris ALAT.280 No pile duct Necropsied specimer: Diabetis Mellitis Viramin K Prednisolone AFA1/AUT/nor Ascris AN-ASM-LKM1- ALAT.280 No pile duct Necropsied specimer: Diabetis Mellitis Viramin K Prednisolone AFA1/AUT/NO Kim et al.* SA AN-ASM-LKM1- No pile duct <t< td=""><td></td><td></td><td></td><td></td><td>PAL: 106</td><td></td><td></td><td></td><td></td><td></td></t<>					PAL: 106					
Han et al.* 30 M Farigue SM LKM1- Han et al.* 30 M Farigue ASAT:400 No bile duct Chronic active hepatitis Myasthenia Prednisolone ASAT/AIT nor Aba+ XAN ANA ANA Mount ANA Prednisolone ASAT/AIT nor Aba+ ANA ANA ANA No bile duct Necropsied specimen: Diabetis Mellitis Niramin K Prednisolone ASAT/AIT nor Askwa et al.* T P Jaundice ASAT.230 No bile duct Normuc hepatitis Myasthenia gravis Plasmapheres Plantino Kim et al.* 35 F Pruntils ANA-/ASM- No parenchyma Ano-Normo Diadition Plastimoto's tryroidits Prednisolone Plastmapheres					ANA+					
Han et at."ICkM1-Han et at."30MFaigueASAT: 400No bile ductChronic active hepatitisMyastheniaPrednisoloneASAT/ALT norANA-ANA-ANA-ANA-ANA-ANA-ANA-ANA-ANA-ANA-Aswa et at."T1ANA-ANA-ANA-ANA-ANA-ANA-Askawa et at."TFJaundiceANA-/ASM-LKM1-AscrissANA-/ASM-LKM1-AscrissANA-/ASM-LKM1-AscrissANA-/ASM-LKM1-Hashimoto's thyroiditisPrednisoloneAsTAN-INOKim et at."35FPunitisAscrissANA-/ASM-LKM1-AscrissANA-/ASM-LKM1-Hashimoto's thyroiditisNormal biological specimentsNyasthenia gravisPlasmaphercesAspatitisKim et at."35FPunitisAscrissANA-/ASM-LKM1-AscrissNyasthenia gravisPlasmaphercesAscrissional biological specimentsKim et at."56FPunitisANA-/ASM-LKM1-Ana-/ASM-LKM1-Ana-/ASM-LKM1-Ana-/ASM-LKM1-Ana-/ASM-LKM1-AscrissANA-/ASM-LKM1-No parenchymalChronic non suppurativeNyasthenia gravisPlasmaphercesAscrissional biological specimentsKim et at."56FNormal biologicaAna-/ASM-LKM1-No parenchymalChronic non suppurativeNormal biological specimentsKim et at."56FPunitisAtA-/ASM-LKM1-Normal biologicaAna-/ASM-LKM1-Ana-/ASM-LKM1-Ana-/ASM-LKM1-A					SM-					
Han et al.430MFatigueASAT:400No bile ductChonic active hepatitisMyastheniaPrednisoloneASAT/ALAT norKeaknessALAT: 777dilatationAlAT. 777dilatationalkatalka					LKM1–					
WeaknessALAT: 777dilatationafter 1 monthANA+ANA+ANA+ANA+ANA+Askm-AmANA+ANA-AsitisANA+AsitisAskmattiAstrisAstrisAstrisNeandineAstrisALT: 280dilatationauto immune hepatitisNitamin KAscitisALT: 280dilatationauto immune hepatitisNitamin KAscitisALT: 280dilatationauto immune hepatitisNitamin KKim et al.*35FNav-ASM-LKM-AnA-ASM-LKM-JaundiceANA-ASM-LKM-anormule hepatitisNitamin KAstrisANA-ASM-LKM-anormule hepatitisNitamin KJaundiceANA-ASM-LKM-anormule hepatitisNitamin KAltre tal.*35FLundiceANA-ASM-Altre tal.*56FLoss ofANA-ASM-Altre tal.*31MJaundiceAltre tal.*Altre tal.*31MJaundiceAltre tal.*Altre tal.*31MJaundiceAltre tal.*AnaAltre tal.*Altre tal.*Altre tal.*AnaliseAltre tal.*Altre tal.*Altre tal.*Altre tal.*MJaundiceAltre tal.*Altre tal.*MJaundiceAltre tal.*Altre tal.*MJaundiceAltre tal.*Altre tal.*MJaundiceAltre tal.*Altre tal.*MJaundiceAltre tal.*Altre tal.*MJaundice <td>Han <i>et al.</i>⁴</td> <td>30</td> <td>Σ</td> <td>Fatigue</td> <td>ASAT: 400</td> <td>No bile duct</td> <td>Chronic active hepatitis</td> <td>Myasthenia</td> <td>Prednisolone</td> <td>ASAT/ALAT normal</td>	Han <i>et al.</i> ⁴	30	Σ	Fatigue	ASAT: 400	No bile duct	Chronic active hepatitis	Myasthenia	Prednisolone	ASAT/ALAT normal
ANA+ANA+ $ASW-JAM ASM-JAM ASW-JAM ASM-JAM ASW a et al.^5$ IAM $ASW-JAM ASM-JAM ASW a et al.^5$ $AST: 322$ No bile ductNetropsied specimen:Diabetis MellitisVitamin KDied from acut $AscitisALAT: 280dilatationauto immune hepatitisMyasthenia gravisPlasmapheresehepatitisAscitisAAT: 220or bile ductAron supurativeNoNoNoNoral biologyIaundiceANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI-Hashimoto's thyroiditisNoral biologyIaundiceANA-/ASM-LKMI ANA-/ASM-LKMI Aron supurativeNoNoNoral biologyJaundiceANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI-Altro Aron SourceANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI ANA-/ASM-LKMI AAA-/ASM-LKMI AAA-/ASM-AM-/ASM-AAA-/ASM-AM-/ASM-AM-/ASM-AMA-/ASM-AMA-/ASM-AMA-/ASM-AMA-/ASM-AMA-/ASM-AMA-/ASM-AMA-/ASM-AMA-/ASM-AAA-/ASM-AMA-/AMA-/$				Weakness	ALAT: 777	dilatation				after 1 month
Askawa et at A scitisASM-JAM- AscitisASM-JAM- AscitisASM-JAM- AscitisAsmant AscitisAsmant AscitisAsmant AscitisDiad from acut AscitisDiad from acut 					ANA+					
Askwa et al.5TFJaundiceASAT: 392No bile ductNecropsied specimen:Diabetis MutationVitamin KDied from acutAscitisALAT: 280dilatationauto immune hepatitisMyasthenia gravisPlasmapheresehepatitisFatigueANA-/ASM-LKM1-Hashimoto's thyroiditisNoUrsodeoxyNormal biologyKim et al.635FPuntitisASAT: 125No parenchymalChronic non suppurativeNoUrsodeoxyNormal biologyJaundiceALAT: 22or bile ductdestructive cholongitisNoUrsodeoxyNormal biologyAigner et al.756FLoss ofASAT: 1912Not mentionedAlHAlH revealing thymomafor 36 monthsAigner et al.756FLoss ofASAT: 1312Not mentionedAlHMyasthenia gravis afterPredisoneNormal biologyAigner et al.756FLoss ofASAT: 1312Not mentionedAlHMyasthenia gravis afterPredisoneNormal biologyAigner et al.756FLoss ofASAT: 1312Not mentionedAlH revealing thymomafor 48 monthsJaundiceAlAT: 1332AlAT: 1332Not mentionedAlH revealing thymomafor 48 monthsJaundiceAlAT: 249dilatationAlH revealing thymomaPredisoneNormal biologyYapali et al.831MJaundiceAlAT: 249dilatationPredisoreNormal biologyYapali et al.831MJaundi					ASM-/AM-					
Kim et al.*AscitisALAT: 280dilatationauto immune hepatitisMyasthenia gravisPlasmapheresehepatitisFaigue $ANA-/ASM-LKM1 ANA-/ASM-LKM1-$ Hashimoto's thyroiditisHashimoto's thyroiditisNormal biologyKim et al.*35FPruritis $ASAT: 125$ No parenchymalChronic non suppurativeNoUr sodeoxyNormal biologyJaundice $ALAT: 22$ or bile ductdestructive cholongitisNoUr sodeoxyNormal biologyAigner et al.*56FLoss of $ASAT: 1912$ Not mentionedAlHMyasthenia gravis afterPredisoneNormal biologyAigner et al.*56FLoss of $ASAT: 1912$ Not mentionedAlHMyasthenia gravis afterPredisoneNormal biologyAigner et al.*51MJaundice $ALAT: 1332$ Not mentionedAlHRvealing thymomafor 48 monthsYapali et al.*31MJaundice $ASAT: 370$ No bile ductAcute liver hepatitisMyasthenia gravisPredisoneNormal biologyYapali et al.*31MJaundice $ASAT: 370$ No bile ductAcute liver hepatitisMyasthenia gravisPredisoneNormal biologyYapali et al.*31MJaundice $ASAT: 370$ No bile ductAcute liver hepatitisMyasthenia gravisPredisoloneNormal biologyYapaliAJaundice $ALAT: 232$ NoNo bile ductAcute liver hepatitisMyasthenia gravisPr	Askawa <i>et al.</i> 5	77	щ	Jaundice	ASAT: 392	No bile duct	Necropsied specimen:	Diabetis Mellitis	Vitamin K	Died from acute
Kim et al.6FatigueANA-/ASM-LKM1-Hashimoto's thyroiditisKim et al.635FPruritisASAT: 125No parenchymalChronic non suppurativeNoUrsodeoxyNormal biologyJaundiceALAT: 22or bile ductdestructive cholongitisNoUrsodeoxyNormal biologyAlar. 22or bile ductdestructive cholongitisChoric acidfor 36 monthsAlar. 22abnormalitiesANA+/ASM-abnormalitiesChoric acidfor 36 monthsAlgner et al.756FLoss ofANA+/ASM-AnormalitiesNormal biologyAlgner et al.756FLoss ofASAT: 1912Not mentionedAlHAlH revealing thymomafor 48 monthsAlgner et al.756FLoss ofANA-SMNot mentionedAlHAlH revealing thymomafor 48 monthsAlgner et al.751MJaundiceAlat: 1332AldAlth revealing thymomafor 48 monthsVapali et al.831MJaundiceANA-SMNo bile ductAcute liver hepatitisMyasthenia gravis afterNormal biologyVapali et al.831MJaundiceAlA-T: 1322No bile ductAcute liver hepatitisMyasthenia gravis after 6 monthsVapali et al.831MJaundiceAlA-T: 232No bile ductAcute liver hepatitisNormal biologyVapali et al.831MJaundiceAlA-T: 232NoNo bile ductAcute liver hepatitisNormal biology <td< td=""><td></td><td></td><td></td><td>Ascitis</td><td>ALAT: 280</td><td>dilatation</td><td>auto immune hepatitis</td><td>Myasthenia gravis</td><td>Plasmapherese</td><td>hepatitis</td></td<>				Ascitis	ALAT: 280	dilatation	auto immune hepatitis	Myasthenia gravis	Plasmapherese	hepatitis
Kim et al.635FPruritisASAT: 125No parenchymalChronic non suppurativeNoUrsodeoxyNormal biologyJaundice $ALAT: 22$ or bile ductdestructive cholongitisChloric acidfor 36 monthsJaundice $ALAT: 22$ or bile ductdestructive cholongitisChloric acidfor 36 monthsLaundice $ALAT: 422$ abnormalities $Chloric acidfor 36 monthsLaundiceANA+/ASM-abnormalitiesChloric acidfor 36 monthsLaundiceANA+/ASM-abnormalitiesALAT: 1322Not mentionedAHAigner et al.756FLoss ofASAT: 1912Not mentionedAHAHAigner et al.756FLoss ofASAT: 1312Not mentionedAHAHAHAigner et al.756FLoss ofAAAT: 1332Not mentionedAHAHAHAHAigner et al.831MJaundiceAAAT: 1332Not mentionedAHAHAHAHYapali et al.831MJaundiceAAAT: 1332Not bile ductAcute liver hepatitisAHAHAHAHYapali et al.831MJaundiceAAT: 1232No bile ductAcute liver hepatitisAHAHAHAHYapali et al.831MJaundiceAAT: 1232No bile ductAcute liver hepatitisAHAHAHAHYapal$				Fatigue	ANA-/ASM-LKM1-			Hashimoto's thyroiditis		
JaundiceALAT: 22or bile ductdestructive cholongitischloric acidfor 36 monthsFatigue $AN4+/ASM-$ abnormalities $LKM1-/AM-$ abnormalitieschloric acidfor 36 monthsKM1-/AM- $LKM1-/AM-$ abnormalities $LKM1-/AM-$ abnormalitieschloric acidfor 36 monthsAigner <i>et al.</i> ¹ 56FLoss of $ASAT: 1912$ Not mentioned AIH Myasthenia gravis afterPredisoneNormal biologyAigner <i>et al.</i> ¹ 56FLoss of $ASAT: 1912$ Not mentioned AIH AIH revealing thymomafor 48 monthsAigner <i>et al.</i> ¹ 31MJaundice $ASAT: 370$ No bile duct $Acute liver hepatitisMyasthenia gravisfor 48 monthsYapali et al.831MJaundiceASAT: 370No bile ductAcute liver hepatitisMyasthenia gravisfor 48 monthsYapali et al.831MJaundiceASAT: 370No bile ductAcute liver hepatitisMyasthenia gravisfor 48 monthsYapali et al.831MJaundiceASAT: 370No bile ductAcute liver hepatitisMyasthenia gravisfor 48 monthsYapali et al.831MJaundiceASAT: 370No bile ductAcute liver hepatitisMyasthenia gravisfor 60 monthsYapali et al.8Al.Al.Al.Acute liver hepatitisMyasthenia gravisfor 60 monthsYapali et al.8Al.Al.Al.Al.Al.$	Kim <i>et al.</i> ⁶	35	ш	Pruritis	ASAT: 125	No parenchymal	Chronic non suppurative	No	Ursodeoxy	Normal biology
Aigner et al. ⁷ 56 F Loss of ASAT: 1912 Not mentioned AIH Myasthenia gravis after Predisone Normal biology Aigner et al. ⁷ 56 F Loss of ASAT: 1912 Not mentioned AIH Myasthenia gravis after Predisone Normal biology Aigner et al. ⁸ 31 M Jaundice ANA/ASM/ Not bile duct Acute liver hepatitis Myasthenia gravis after Predisone Normal biology Yapali et al. ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali et al. ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali et al. ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali M Jaundice ALAT: 249 dilatation Connective tissue After 6 months Sister Patigue Patigue ALAT: 249 dilatation Connective tissue After				Jaundice	ALAT: 22	or bile duct	destructive cholongitis		chloric acid	for 36 months
Aigner <i>et al.</i> ⁷ 56 F Loss of AST: 1912 Not mentioned AIH Myasthenia gravis after Predisone Normal biology appetitis ALAT: 1332 ALAT: 1332 AIH revealing thymoma for 48 months Jaundice ANA/ASM/ Yapali <i>et al.</i> ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Fatigue ALAT: 249 dilatation Hashimoto's Thyroiditis After 6 months Nausea PAL: 152 GT: 208 ANA-/ASM- AM-				Fatigue	ANA+/ASM-	abnormalities				
Aigner et al.7 56 F Loss of ASAT: 1912 Not mentioned AIH Myasthenia gravis after Predisone Normal biology Papetitis ALAT: 1332 ALAT: 1332 ALAT: 1332 AIH revealing thymoma for 48 months Paundice ANA/ASM/ AIH revealing thymoma for 48 months Yapali et al.8 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali et al.8 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali et al.8 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali et al.8 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapatis M Jaundice ALT: 152 Connective tissue GT: 208 AnA-/ASM- ANA-/ASM- ANA-/ASM					LKM1–/AM–					
Appetitis ALT: 1332 AIH revealing thymoma for 48 months Jaundice ANA/ASM/ Jaundice ANA/ASM/ for 48 months Yapali <i>et al.</i> ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali <i>et al.</i> ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali Fatigue ALAT: 249 dilatation Hashimoto's Thyroiditis after 6 months Nausea PAL: 152 GT: 208 GT: 208 disorder disorder ANA-/ASM- ANA-/ASM- Ana-/ASM- Ana-/ASM- Ana-/ASM-	Aigner <i>et al.</i> 7	56	ш	Loss of	ASAT: 1912	Not mentioned	AIH	Myasthenia gravis after	Predisone	Normal biology
Jaundice ANA/ASM/ Yapali <i>et al.</i> ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Yapali <i>et al.</i> ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Fatigue ALAT: 249 dilatation Hashimoto's Thyroiditis after 6 months Nausea PL: 152 Connective tissue GT: 208 AnA-/ASM- ANA-/ASM- AM- AM- AM-				appetitis	ALAT: 1332			AIH revealing thymoma		for 48 months
Yapali et al. ⁸ 31 M Jaundice ASAT: 370 No bile duct Acute liver hepatitis Myasthenia gravis Prednisolone Normal biology Fatigue ALAT: 249 dilatation Hashimoto's Thyroiditis after 6 months Nausea PL: 152 Connective tissue after 6 months GT: 208 GT: 208 disorder ANA-/ASM- AM-				Jaundice	ANA/ASM/					
Fatigue ALAT: 249 dilatation Hashimoto's Thyroiditis after 6 months Nausea PAL: 152 Connective tissue after 6 months GT: 208 GT: 208 disorder after 6 months ANA-/ASM- ANA-/ASM- AM-	Yapali <i>et al.</i> ⁸	31	Σ	Jaundice	ASAT: 370	No bile duct	Acute liver hepatitis	Myasthenia gravis	Prednisolone	Normal biology
Nausea PAL: 1.52 Connective tissue GT: 208 disorder ANA-/ASM- AM-				Fatigue	ALAT: 249	dilatation		Hashimoto's Thyroiditis		after 6 months
GT: 208 disorder ANA-/ASM- AM-				Nausea	PAL: 152			Connective tissue		
ANA-/ASM- AM-					GT: 208			disorder		
AM-					ANA-/ASM-					
					AM-					

÷ 4 ų ÷

5 ב<u>-</u> w, mare, r, remare, ASAT, aspandate antimotiansterase, ALAT, aramite antinotransterase, FAC, arkame prospiratase, 91, 94 antibody; ASM, anti smooth muscle antibody; AM, anti mitochondrial antibody; LKM1, anti liver/kidney microsome antibody. INI, Male, F, Temale, Abal, aspartate am

Cancer Biol Med Vol 10, No 3 September 2013

Discussion

Chemotherapy can be an efficient treatment of paraneoplastic disorders. This case is a combination of two autoimmune diseases associated with thymoma: type I diabetes mellitus, which occurred when thymoma was first diagnosed, and AIH. We cannot ensure that the diabetes was totally related to the thymoma, but based on chronological events and the absence of familial history, we considered it as a paraneoplastic syndrome. AIH was diagnosed with disease recurrence, but its onset was difficult to define. Signs of fibrosis suggest chronic evolution. All cases published in literature are summarized in Table 2. In these cases. AIH appeared a few months after the diagnosis of thymoma in 1 case⁴ but was synchronous to diagnosis in the other cases^{3,5}. Most patients were from Asia, leading us to ask about genetic factors associated with high risk of AIH. Most patients were young, with a median age of 39 years. All 4 females and 2 males had no specific clinical presentation. AIH is generally revealed by biological liver dysfunction, with elevated liver enzymes (ASAT/ALAT). In our case, liver enzymes were slightly abundant, but major biological cholestasis was observed. The only case in literature on cholestasis associated with thymoma is related to autoimmune cholangitis⁵.

Liver biopsy is always necessary to confirm diagnosis, which relies on the criteria of the International AIH Group⁹. The International AIH Scoring System considers several parameters, such as gender, liver enzymes, antibodies, and concurrent autoimmune disease. Once the patient obtains a score of 15 before treatment or of 17 after treatment, the diagnosis of AIH is definite^{9,10}.

Thymoma is a slow-growing disease that generally leads to liver failure, if not treated, in 50% of cases. The main treatment based on steroids and azathioprine can prevent evolution to cirrhosis. Asakawa *et al.*⁵ reported a case of AIH with rapid liver failure and death in the absence of a specific treatment of thymoma. In this case, the patient did not receive azathioprine because of the high risk of immune deficiency associated with chemotherapy and did not receive steroids because cytolysis was not profound. Cholestasis decreased markedly after chemotherapy alone. In a case reported by Asakawa, the fact that the patient could not be operated on her thymoma may explain the fatal evolution. In this case, chemotherapy allowed complete response on the primary tumor and corrected hepatic disorder.

Our hypothesis is also highlighted by the clinical and molecular data reported by Aigner⁷, who showed the presence of LKM-3 and UGT 1 antibody (UDP glutamyl-transferase involved in AIH) in the patient's serum, liver, and thymoma tissue. After thymectomy, these antibodies were not found in the serum of the patient. This paper showed the paraneoplastic origin of AIH (which occurred before the diagnosis of thymoma) and the effect

of the surgical removal of the primary tumor on correcting this disorder. The active chemotherapy drugs are anthracyclines, cisplatine, and cyclophosphamide. New-generation chemotherapy drugs (pemetrexed, docetaxel, and irinotecan) produced controversial results. If the tumor seems responsive after 3 cycles, it is recommended to consolidate with 3 more cycles. Thymoma is a radiosensitive tumor and residual disease can be monitored with complementary mediastinal radiotherapy¹¹. Unlike already published cases, multimodality treatment using chemotherapy and radiotherapy was sufficient to control both the primary tumor and the paraneoplastic hepatic disorder of our patient.

Conclusion

Thymoma is associated with the high rate of paraneoplastic autoimmune diseases among AIH that should be considered in the etiological diagnosis of hepatic disorders in thymoma. In this case, based on chronological arguments, we speculated that AIH and diabetes mellitus are induced by thymoma. Specific treatments of the primary tumor may treat AIH. Immunosuppressors and steroids should be used only in case of severe evolution or a persistent paraneoplastic disorder.

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

- Ströbel P, Marx A, Zettl A, Müller-Hermelink HK. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today 2005;35:805-811.
- Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5:S260-265.
- Ko KF, Ho T, Chan KW. Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 1995;59:558-559.
- Han YS, Kim BH, Kim TH, Dong SH, Kim HJ, Chang YW, et al. Autoimmune hepatitis in a patient with myasthenia gravis and thymoma-a report on the first case in Korea. Korean J Intern Med 2000;15:151-155.
- Asakawa H, Kashihara T, Fukuda H, Yamamoto M. A patient with thymoma and four different organ-specific autoimmune disease. Neth J Med 2002;60:292-295.
- Kim JH, Kim BH, Kim YW, Park JC, Jung YH, Lee BO, et al. Autoimmune cholangitis in a patient with thymoma. Journal of gastroenterology and hepatology 2004;19:1324-1327.
- 7. Aigner E, Strassburg CP, Strasser M, Pohla-Gubo G, Dietze O,

Hutter J, et al. Transient autoimmune hepatitis induced by a thymoma. Am J Gastroenterol 2009;104:1332-1334.

- Yapali S, Oruc N, LLgum S, Yilmaz F, Aksu K, Yimlaz M, et al. Acute presentation of autoimmune hepatitis in a patient with myasthenia gravis, thymoma, Hashimoto thyroiditis and connective tissue disorder. Hepatol Res 2012;42:835-839.
- 9. Johnson PJ, McFarlane IG. Meeting report: international autoimmune hepatitis group. Hepatology1993;18:998-1005.
- 10. Czaja A, Carpenter HA. Validation of scoring system for diagnosis

of autoimmune hepatitis. Dig Dis Sci 1996;41:305-314.

 Pescarmona E, Rendina EA, Venuta F, D'Arcangelo E, Pagani M, Ricci C, et al. Analysis of prognostic factors and clinicopathological staging of thymoma. Ann Thorac Surg 1990;50:534-538.

Cite this article as: Mejri N, Chabchoub I, Gargouri I, Belaid I, Ezairi F, Hmissa S, Ben Ahmed S. Effect of chemotherapy on autoimmune hepatitis in thymoma: a case report and literature review. Cancer Biol Med 2013;10:169-173. doi: 10.7497/j.issn.2095-3941.2013.03.008